Changes in serum uric acid levels and cardiovascular events: A meta-analysis

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 8, 2013, Pages 707-714

  Savarese, G ^a   Ferri, C ^b   Trimarco, B ^a   Rosano, G ^c   Dellegrottaglie, S ^a   Losco, T ^a   Casaretti, L ^a   D'Amore, C ^a   Gambardella, F ^a   Prastaro, M ^a   Rengo, G ^a   Leosco, D ^a   Perrone Filardi, P ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Hyperuricaemia; Risk factors; Risk stratification; Uric acid

Indexed keywords

URIC ACID;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; HUMAN; HYPERURICEMIA; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; RISK FACTOR; RISK STRATIFICATION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

HYPERURICAEMIA; RISK FACTORS; RISK STRATIFICATION; URIC ACID;

CARDIOVASCULAR DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; URIC ACID;

EID: 84880045941     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2013.03.001     Document Type: Article

References (44)

1. Kawai T., Ohishi M., Takeya Y. Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients. Hypertens Res 2012, 35:1087-1092.
2. Masuo K., Kawaguchi H., Mikami H., Ogihara T., Tuck M.L. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003, 42:474-480.
3. Yang T., Chu C.H., Bai C.H., You S.L., Chou Y.C., Hwang L.C., et al. Uric acid concentration as a risk marker for blood pressure progression and incident hypertension: a Chinese cohort study. Metabolism 2012, 61:1747-1755.
4. Milionis H.J., Kakafika A.I., Tsouli S.G., Athyros V.G., Bairaktari E.T., Seferiadis K.I., et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 2004, 148:635-640.
5. Niskanen L., Laaksonen D.E., Lindström J., Eriksson J.G., Keinänen-Kiukaanniemi S., Ilanne-Parikka P., et al. Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetes Care 2006, 29:709-711.
6. Fang J., Alderman M.H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000, 283:2404-2410.
7. Takayama S., Kawamoto R., Kusunoki T., Abe M., Onji M. Uric acid is an independent risk factor for carotid atherosclerosis in a Japanese elderly population without metabolic syndrome. Cardiovasc Diabetol 2012, 11:2-11.
8. Niizeki T., Takeishi Y., Arimoto T., Okuyama H., Nozaki N., Hirono O., et al. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. J Cardiol 2006, 47:219-228.
9. Kim S.Y., Guevara J.P., Kim K.M., Choi H.K., Heitjan D.F., Albert D.A. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 2010, 62:170-180.
10. Levantesi G., Marfisi R.M., Franzosi M.G., Maggioni A.P., Nicolosi G.L., Schweiger C., et al. Uric acid: a cardiovascular risk factor in patients with recent myocardial infarction. Int J Cardiol 2012, 10.1016/j.ijcard.2011.12.110.
11. Choi H.K., Ford E.S., Li C., Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007, 57:109-115.
12. Krishnan E., Svendsen K., Neaton J.D., Grandits G., Kuller L.H. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008, 168:1104-1110. MRFIT Research Group.
13. Baker J.F., Schumacher H.R., Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology 2007, 58:450-457.
14. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2012, 33:1635-1701.
15. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818. European Association for Cardiovascular Prevention & Rehabilitation.
16. Moher D., Liberati A., Tetzlaff J., Altman D.G. PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269.
17. Detsky A.S., Naylor C.D., O'Rourke K., McGeer A.J., L'Abbé K.A. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992, 45:255-265.
18. Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006, 295:676-680.
19. Sharp S., Sterne J. Meta-analysis. Stata Tech Bull Reprints 1998, 7:100-108.
20. Sharp S.J. Meta-analysis regression. Stata Tech Bull 1998, 42:16-22.
21. Ruilope L.M., Kirwan B.A., de Brouwer S., Danchin N., Fox K.A., Wagener G., et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertens 2007, 25:1711-1718.
22. Brazier M., Grados F., Kamel S., Mathieu M., Morel A., Maamer M., et al. Clinical and laboratory safety of one year's use of a combination calcium+vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2005, 27:1885-1893.
23. Becker M.A., Schumacher H.R., Wortmann R.L., MacDonald P.A., Eustace D., Palo W.A., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461.
24. Goicoechea M., de Vinuesa S.G., Verdalles U., Ruiz-Caro C., Ampuero J., Rincón A., et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010, 5:1388-1393.
25. Berl T., Hunsicker L.G., Lewis J.B., Pfeffer M.A., Porush J.G., Rouleau J.L., et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003, 138:542-549.
26. Smink P.A., Bakker S.J., Laverman G.D., Berl T., Cooper M.E., de Zeeuw D., et al. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials. J Hypertens 2012, 30:1022-1028.
27. Khan F., George J., Wong K., McSwiggan S., Struthers A.D., Belch J.J. Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovasc Ther 2008, 26:247-252.
28. Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
29. Otero M.L., Claros N.M. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. Clin Ther 2005, 27:166-173. Study Investigators Group.
30. Pelemans W., Verhaeghe J., Creytens G., Coupez G., Van Dessel A., Opsomer M., et al. Efficacy and safety of rilmenidine in elderly patients - comparison with hydrochlorothiazide. The Belgian Multicentre Study Group. Am J Cardiol 1994, 74:51A-57A.
31. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
32. Wikstrand J., Westergren G., Berglund G., Bracchetti D., Van Couter A., Feldstein C.A., et al. Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study. JAMA 1986, 255:1304-1310.
33. Ames B.N., Cathcart R., Schwiers E., Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981, 78:6858-6862.
34. Kim S.Y., Guevara J.P., Kim K.M., Choi H.K., Heitjan D.F., Albert D.A. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009, 61:885-892.
35. Wheeler J.G., Juzwishin K.D., Eiriksdottir G., Gudnason V., Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005, 2:e76.
36. Khosla U.M., Zharikov S., Finch J.L., Nakagawa T., Roncal C., Mu W., et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005, 67:1739-1742.
37. Corry D.B., Eslami P., Yamamoto K., Nyby M.D., Makino H., Tuck M.L. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008, 26:269-275.
38. Ruggiero C., Cherubini A., Ble A., Bos A.J., Maggio M., Dixit V.D., et al. Uric acid and inflammatory markers. Eur Heart J 2006, 27:1174-1181.
39. Sánchez-Lozada L.G., Tapia E., Bautista-García P., Soto V., Avila-Casado C., Vega-Campos I.P., et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2008, 294:F710-F718.
40. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
41. Hlatky M.A., Greenland P., Arnett D.K., Ballantyne C.M., Criqui M.H., Elkind M.S., et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416.
42. Kanbay M., Ozkara A., Selcoki Y., Isik B., Turgut F., Bavbek N., et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007, 39:1227-1233.
43. Cappuccio F.P., Strazzullo P., Farinaro E., Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA 1993, 270:354-359.
44. Strazzullo P., Cappuccio F.P., Trevisan M., Iacoviello L., Iacone R., Barba G., et al. Red blood cell sodium-lithium countertransport, blood pressure, and uric acid metabolism in untreated healthy men. Am J Hypertens 1989, 2:634-636.